Medicine and Professor of Physiology at Boston University School of Medicine
. He is also the Chief of Cardiovascular Medicine, Director of the Myocardial Biology Unit, Director of the Cardiomyopathy Program and Co-Director of the Cardiovascular Center at Boston Medical Center.
Howard J. Eisen, M.D., F.A.C.C., F.A.C.P., F.A.H.A., is the Thomas J. Vischer, Professor of Medicine and Chief of the Division of Cardiology at Drexel University, College of Medicine. He is also Director of the Drexel Center for Cardiovascular Disorders and The Center for Advanced Heart Failure Care at Hahnemann University Hospital.
Douglas L. Mann, M.D., F.A.C.C., F.A.C.P., is Chief, Division of Cardiology, Lewin Chair and Professor of Medicine, Washington University in St. Louis, Cardiologist-in-Chief, Barnes Jewish Hospital.
Richard P. Schwarz, Ph.D., is President of CV Ventures, LLC, a consulting firm specialized in the design and execution of clinical trials and an Adjunct Professor at University of Miami.
Jonathan S. Stamler, M.D. is the George Barth Geller Professor of Research in Cardiovascular Diseases and Professor of Medicine and Biochemistry at Duke University.
Dr. Hare stated, "I am pleased to have a group of distinguished colleagues joining me in support of the clinical development program of CDP-1050. Their remarkable clinical experience and expertise is a significant asset of the program. CDP-1050 is a novel directed approach for the treatment of heart failure, and it is gratifying to be involved in what we hope will be a paradigm shift in this disease treatment."
"We are honored to be working with such knowledgeable and experienced individuals in the development of CDP-1050," said Amir Pelleg, Ph.D., Cordex's President and CSO. "Progressive heart failure is a growing and vexing medical problem around the world. It iPage: 1 2 3 4 5 Related biology technology :1
. Cordex Pharma Presents New Frontiers in Cardiovascular Medicines on January 292
. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.3
. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory4
. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes5
. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results6
. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court7
. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results8
. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML9
. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 200710
. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 200711
. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results